New hope for tough bladder cancers: drug tested after standard therapies fail
NCT ID NCT04995419
Summary
This study tested a drug called enfortumab vedotin in Chinese patients with advanced bladder cancer that had spread and stopped responding to standard chemotherapy and immunotherapy. The main goal was to see if the drug could shrink tumors and for how long. Researchers also closely monitored how the drug moved through the body and its safety in this specific patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UROTHELIAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Site CN86001
Beijing, China
-
Site CN86002
Guangzhou, China
-
Site CN86003
Wuhan, China
-
Site CN86004
Shanghai, China
-
Site CN86006
Hangzhou, China
-
Site CN86007
Nanjing, China
-
Site CN86009
Changsha, China
Conditions
Explore the condition pages connected to this study.